LCS
MNTA

Levin Capital Strategies’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Levin Capital Strategies’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,000
Closed -$152K – 422
2015
Q1 		$152K Buy
+10,000
New +$130K ﹤0.01% 374

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Levin Capital Strategies's MNTA Position: Q2 2015 in Review

Levin Capital Strategies sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q2 2015, closing a stake of 10,000 shares — an estimated $152K sold.

Levin Capital Strategies first reported a position in MNTA in Q1 2015 and held it in 1 quarter. The position peaked at $152K in Q1 2015. 162 funds tracked by Wall St. Rank hold MNTA as of Q2 2015.

  • Levin Capital Strategies reported no remaining Momenta Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Levin Capital Strategies sold 10,000 Momenta Pharmaceuticals, Inc. shares in Q2 2015, an estimated $152K.
  • Levin Capital Strategies first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Levin Capital Strategies's Momenta Pharmaceuticals, Inc. position peaked at $152K in Q1 2015.
  • 162 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q2 2015.

Based on Levin Capital Strategies's 13F filing for Q2 2015, filed 12 Aug 2015.